

#### **15 NOVEMBER 2019**

#### **ASX/MEDIA RELEASE**

#### **ISSUE OF PERFORMANCE RIGHTS**

Bardoc Gold Limited (ASX: BDC, Bardoc or the Company) advises that the company will issue a total of 3,800,000 Performance Rights to new management and staff under the terms of the Performance Rights and Option Plan approved by shareholders. The Performance Rights will not vest, nor any underlying shares be issued, unless the performance conditions set by the Board have been achieved. Performance Rights issued form an important part of the renumeration packages for new staff members and provide incentives linked to increases in shareholder value.

The following table outlines key business and retention objectives with vesting terms of four years: -

Unlisted Performance Rights	Class H	Class I
Number to be issued	1,900,000	1,900,000
Principle Terms /Vesting Conditions	as invalidity, bona fide redundate employed or engaged with the Class I  The Bardoc Board resolving Condition)  10-day BDC VWAP being greated Other than for reasons outside	on); er than \$0.14 per Share of the control of the Holder (such ancy, or death) the holder remains Company for 12 months.  for a decision to mine (Decision er than \$0.18 per Share of the control of the Holder (such ancy, or death) the holder remains
Issue Price	Nil	

#### For further information contact:

#### **INVESTORS:**

Robert Bardoc Gold Limited

Ryan

Telephone: (08) 6215 0090

Email: admin@bardocgold.com.au

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

## **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

 $Introduced \ o1/o7/96 \ \ Origin: Appendix \ 5 \ \ Amended \ o1/o7/98, \ o1/o9/99, \ o1/o7/oo, \ 30/o9/o1, \ 11/o3/o2, \ o1/o1/o3, \ 24/10/o5, \ o1/o8/12, \ o4/o3/13$ 

Name of	f entity	
Bardoo	Gold Limited	
4 DNI		
ABN		
40 125	578 743	
We (th	ne entity) give ASX the following	information.
Part	1 - All issues	
You mus	st complete the relevant sections (attach	sheets if there is not enough space).
1	*Class of *securities issued or to be issued	<ol> <li>Unlisted Performance Rights – Class H</li> <li>Unlisted Performance Rights – Class I</li> </ol>
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	1.) 1,900,000 2.) 1,900,000

<sup>+</sup> See chapter 19 for defined terms.

- Principal terms of the \*securities (e.g. if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)
- 1.) Class H 4 year term
- the Delivery of a Bardoc Pre-Feasibility Study to the Board's satisfaction (Feasibility condition);
- 10-day BDC VWAP being greater than \$0.14 per Share
- Other than for reasons outside of the control of the Holder (such as invalidity, bona fide redundancy, or death) the holder remains employed or engaged with the Company for 12 months.
- 2.) Class I- 4 year term
- The Bardoc Board resolving for a decision to mine (Decision Condition)
- 10-day BDC VWAP being greater than \$0.18 per Share
- Other than for reasons outside of the control of the Holder (such as invalidity, bona fide redundancy, or death) the holder remains employed or engaged with the Company for 24 months

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Any shares issued on vesting and subsequent Do the \*securities rank equally in 4 exercise will rank equally from the date of issue all respects from the +issue date with the existing ordinary shares on issue with an existing +class of quoted +securities? If the additional \*securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment Nil Issue price or consideration 5 6 Purpose of the issue Staff Incentive Performance Rights in accordance with the Bardoc Performance Rights and Option (If issued as consideration for the acquisition of assets, clearly Plan approved by shareholders. identify those assets) 6a Yes Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i The date the security holder 28 November 2018 6b resolution under rule 7.1A was passed N/A 6c Number of \*securities issued without security holder approval under rule 7.1

<sup>+</sup> See chapter 19 for defined terms.

#### Appendix 3B New issue announcement

6d	Number of *securities issued with security holder approval under rule 7.1A	N/A	
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
6f	Number of *securities issued under an exception in rule 7.2	Class H Performance Rig Class I Performance Righ	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
		<b>-</b>	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	Rule 7.1 – 69,795,530 Rule 7.1A – 4,241,195	
		<b>r</b> -	
7	<sup>+</sup> Issue dates	18 <sup>th</sup> November 2019	
	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.  Cross reference: item 33 of Appendix 3B.		
		Number	<sup>+</sup> Class
8	Number and +class of all +securities quoted on ASX	1,378,085,721	Fully paid ordinary shares

(including the \*securities in

section 2 if applicable)

Appendix 3B Page 4 04/03/2013

12,000,000

Fully paid ordinary shares (Escrowed until 13<sup>th</sup> August 2020)

<sup>+</sup> See chapter 19 for defined terms.

9 Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)

Number	+Class	
650,000	45c November 2019 Share options	
18,000,000	16c March 2021 Share options	
3,000,000	16c May 2020 Share options	
7,900,000	16c March 2021 Share Options	
4,000,000	5c February 2021 Share Options	
3,000,000	20c September 2022 Share Options	
75,892,500	16c December 2020 Share Options	
6,000,000	12c September 2022 Share Options	
4,000,000	Class A Performance Rights (Vested)	
5,000,000	Class B Performance Rights (Vested)	
1,650,000	Class C Performance Rights	
1,650,000	Class D Performance Rights	
8,000,000	Class E Performance Rights	
21,300,000	Class F Performance Rights	
20,300,000	Class G Performance Rights	
1,900,000	Class H Performance Rights	
1,900,000	Class I Performance Rights	

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

N/A			

#### Part 2 - Pro rata issue

11	Is security holder approval required?	
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the *securities will be offered	
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	
15	<sup>+</sup> Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	

<sup>+</sup> See chapter 19 for defined terms.

#### Appendix 3B New issue announcement

17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has security holders who will not be sent new offer documents  Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	
25	If the issue is contingent on security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

29	Date rights trading will end (if applicable)	
30	How do security holders sell their entitlements in full through a broker?	
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	
32	How do security holders dispose of their entitlements (except by sale through a broker)?	
33	<sup>+</sup> Issue date	
	3 - Quotation of securities d only complete this section if you are applying for quotation of securities	
34	Type of *securities (tick one)	
(a)	√ +Securities described in Part 1	
(b)	All other <sup>+</sup> securities  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities	
Entitie	es that have ticked box 34(a)	
Additi	onal securities forming a new class of securities	
Tick to docum	indicate you are providing the information or ents	
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders	
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories	
<u> </u>		
+ See ch	apter 19 for defined terms.	

o4/o3/2013 Appendix 3B Page 7

37	1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over  A copy of any trust deed for t	the additional †securities	
Entitie	es that have ticked box 34(b)		
38	Number of *securities for which *quotation is sought	N/A	
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought	N/A	
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  If the additional *securities do not rank equally, please state: a) the date from which they do b) the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment c) the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	N/A	
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period  (if issued upon conversion of another +security, clearly identify that other +security)	N/A	
		Number	+Class

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Number and +class of all +securities quoted on ASX (including the +securities in clause 38)

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 15<sup>th</sup> November 2019

Company secretary
Print name: Russell Hardwick

<sup>+</sup> See chapter 19 for defined terms.

# **Appendix 3B – Annexure 1**

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital			
Step 1: Calculate "A", the base figure from which the placement capacity is calculated			
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	915,695,740		
<ul> <li>Add the following:</li> <li>Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval</li> <li>Number of partly paid +ordinary securities that became fully paid in that 12 month period</li> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	5,000,000 (13 March 2019) 110,056,996 (30 April 2019) 31,785,000 (25 October 2019) 83,430,426 (13 March 2019) 91,569,574 (13 March 2019) 4,874,222 (13 March 2019)		
Subtract the number of fully paid  +ordinary securities cancelled during that 12 month period			
"A"	1,242,411,958		

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]
<b>Multiply</b> "A" by 0.15	186,361,793
Step 3: Calculate "C", the amount 7.1 that has already been used	of placement capacity under rule
<ul> <li>Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:</li> <li>Under an exception in rule 7.2</li> <li>Under rule 7.1A</li> <li>With security holder approval under</li> </ul>	4,000,000 Share Options (13 March 2019) 15,673,763 Ordinary Shares (30 April 2019) 3,000,000 Share Options (11 September 2019)
<ul> <li>rule 7.1 or rule 7.4</li> <li>Note: <ul> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> </ul>	60,000,000 Share Options (27 September 2019) 6,000,000 Share Options (27 September 2019) 15,892,500 Share Options (25 October 2019) 12,000,000 Ordinary Shares (13 <sup>th</sup> November 2019)
"C"	116,566,263
Step 4: Subtract "C" from ["A" x " placement capacity under rule 7.1	-
"A" x 0.15	186,361,793
Note: number must be same as shown in Step 2	
Subtract "C"	116,566,263
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.15] – "C"	69,795,530
	[Note: this is the remaining placement capacity under rule 7.1]

<sup>+</sup> See chapter 19 for defined terms.

### Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"		
Note: number must be same as shown in Step 1 of Part 1	1,242,411,958	
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10	124,241,195	
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A		
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	120,000,000 Ordinary shares (27 September 2019)	
"E"	120,000,000	

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	124,241,195
Note: number must be same as shown in Step 2	
Subtract "E"	120,000,000
Note: number must be same as shown in Step 3	
<b>Total</b> ["A" x 0.10] – "E"	4,241,195
	Note: this is the remaining placement capacity under rule 7.1A

<sup>+</sup> See chapter 19 for defined terms.